ReviewCurrent oncology reports2024
Liver Cancer Etiology: Old Issues and New Perspectives.
Review in Current oncology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Astragaloside IV and rapamycin co-loaded bone marrow mesenchymal stem cell-derived exosome nanocarriers for targeted modulation of the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.Nanomedicine (London, England) · 2026Article
- Integrative systems biology and transcriptomic database analysis (GEPIA2 and TNMplot) uncover HRAS-driven anticancer mechanisms of anthraquinones in liver cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- A multi-centre, prospective trial of a methylation-based liquid biopsy for early detection of liver cancer in high-risk populations.Clinical and translational medicine · 2026Article
- Advances in targeting vasculogenic mimicry in malignant tumors using monomeric compounds from Traditional Chinese Medicine (Review).Oncology letters · 2026Review
- Stemness CD24 activation promotes hepatocellular carcinoma progressionWorld journal of gastroenterology · 2026Article
- Regulatory Effects of Coffee/Chlorogenic Acid and Tea/Epigallocatechin-3-Current issues in molecular biology · 2025Review
- Effects of the Polar Fraction ofInternational journal of molecular sciences · 2025Article
- Changes in nutritional status in hepatocellular carcinoma patients treated with sorafenib.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Liver Tumor Segmentation Based on Multi-Scale Deformable Feature Fusion and Global Context Awareness.Biomimetics (Basel, Switzerland) · 2025Article
- Recent Advances in the Mechanisms and Applications ofMolecules (Basel, Switzerland) · 2025Review
- Up-regulated programmed cell death protein-1/its ligand 1 expression promotes metabolic dysfunction-associated steatotic liver disease malignant progression.World journal of gastrointestinal oncology · 2025Article
- Rural-Urban Disparity in Premature Cancer Mortality in Young People Aged 15-44 Years in China, 2004-2021.International journal of public health · 2025Article
- Gamma-Glutamyl Transpeptidase to Neutrophil Ratio: Prognostic Indicator for Hepatocellular Carcinoma Patients Post-Curative Resection [Letter].Journal of hepatocellular carcinoma · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review aims to synthesize the old issues and current understandings of the etiology of liver cancer, focusing on the diverse causative factors influenced by geographical, socioeconomic, and lifestyle variations across different regions. RECENT
findingsWe highlight significant geographic disparities in liver cancer risk factors. While hepatitis B and C viruses, aflatoxin exposure, and alcohol consumption remain globally established contributors; metabolic dysfunction-associated steatotic liver disease and metabolic syndromes are increasingly prominent in the West. Chronic HBV and aflatoxin continue to dominate as risk factors in Asia and Africa. Dietary factors, metabolic diseases like diabetes and obesity, genetic predispositions, environmental risk factors and lifestyle choices such as smoking and alcohol use play substantial roles in specific populations. Protective factors like coffee and tea consumption, along with aspirin use, vegetables and fruits have shown potential in reducing HCC risk, although findings vary by population and dietary habits. Liver cancer etiology is influenced by various factors that differ by region. Established risk factors include hepatitis B and C, aflatoxin, and alcohol. Emerging risks, such as metabolic dysfunction-associated steatotic liver disease, are more prevalent in Western countries, while aflatoxin and HBV remains significant in Asia and Africa. Diet, metabolic conditions like diabetes and obesity, genetic predispositions, and lifestyle choices also play crucial roles. Coffee, tea, aspirin, vegetables, and fruits may reduce HCC risk, but effectiveness varies. Future research should integrate epidemiology, genetics, and nutrition, with global cooperation and data sharing essential for effective cancer control strategies.
Indexed as
Identifiers
39388026What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.